Cat. #161352
MCF10A-EGFR1m-18 cell line
Cat. #: 161352
Sub-type: Continuous
Availability: 8-10 weeks
Organism: Human
Tissue: Mammarygland epithelium
Model: Mutant
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Motoki Takagi
Institute: Fukushima Medical University
Primary Citation: Hoshi et al. Oncol Rep. 2017 Jan, 37(1):66-76. PMID: 27840973
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MCF10A-EGFR1m-18 cell line
- Alternate name: 06M01030
- Cancers detailed: Non-tumorigenic
- Tool sub type: Continuous
- Parental cell: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
- Clone: EGFR-1_type-25
- Organism: Human
- Tissue: Mammarygland epithelium
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Mutant
- Model description: Type: Type-25; Type mutation: T790M, L858R; CDS mutation: c.2369C>T, c.2573T>G; AA mutation: p.T790M, p.L858R; COSMIC Mutation ID: -; Note: Multi-site mutation
- Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related genes. EGFR (epidermal growth factor receptor). EGFR is a trans-membrane type receptor tyrosine kinase and signaling caused by EGFR is thought to play a crucial role in maintaining homeostasis of normal tissues by being involved in the regulation of cells such as proliferation and differentiation. Mutation of EGFR gene is found in lung cancer and it is known that its constant activation causes cell proliferation and tumorigenesis. Deletion of the Exon19 region, mutation of L858R and T790M are known as somatic cell mutations often found in cancer.
- Application: Functional analysis of mutated genes, Drug screening
- Biosafety level: 1
Target Details
- Target: Epidermal growth factor receptor [EGFR]
- Target background: Gene ID: 1956; References: DNA (mRNA): NM_005228.3; Protein: NP_005219.2
Applications
- Application: Functional analysis of mutated genes, Drug screening
Handling
- Format: Frozen
- Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 µg/ml insulin (human, recombinant), 5 µM forskolin, 0.5 µg/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 µg/ml streptomycin
- Temperature: 37° C
- Atmosphere: Humidified incubator with 5% CO2
- Shipping conditions: Dry ice
- Storage medium: CELLBANKER 2 (Zenogen pharma)
- Storage conditions: Liquid Nitrogen
- Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
- Cultured in antibiotics: 100 U/ml Penicillin, and 100 µg/ml Streptomycin
- Mycoplasma free: Yes
- Characterisation tests: Comprehensive gene expression analysis, Identification of cell proliferation and cellular form, Drug sensitivity tests
References
- Hoshi et al. Oncol Rep. 2017 Jan, 37(1):66-76. PMID: 27840973